The pharmacokinetics and safety of porfimer after repeated administration 30–45 days apart to patients undergoing photodynamic therapy

作者：Stephen P. Pereira, Lakshmana Ayaru, Roger Ackroyd, David Mitton, Grant Fullarton, M. Zammit, Z. Grzebieniak, Helmut Messmann, Maria-Anna Ortner, Lan Gao, My Thi Ha Trinh, Jean Spénard · 发表于：Alimentary Pharmacology & Therapeutics · 年份：2010 · DOI：10.1111/j.1365-2036.2010.04400.x · 被引用次数：13 · 研究领域：Photodynamic Therapy Research Studies、Nonmelanoma Skin Cancer Studies、Sinusitis and nasal conditions

BACKGROUND: Porfimer is an intravenous (i.v.) injectable photosensitizing agent used in the photodynamic treatment of tumours and of high-grade dysplasia in Barrett's oesophagus. AIM: To assess the pharmacokinetics as well as the safety profiles of porfimer after a first and a second dose administered 30-45 days apart in patients undergoing photodynamic therapy. METHODS: Nineteen patients (16 with cholangiocarcinoma) were enrolled. Porfimer sodium was administered by i.v. injection over 3-5 min. Blood samples were collected prior to starting i.v. drug injection and postdose at different time points after the first and second administrations. RESULTS: Porfimer exposure values after the second administration were statistically higher than those observed after the first administration, suggesting a slight accumulation of porfimer following repeated administration. The apparent mean elimination half-life of porfimer increased from 410 h after the first administration to 725 h after the second administration. The safety profiles of porfimer after a first and a second administration were similar and did not raise additional concern. Eight patients experienced nine serious adverse events. Only photosensitivity was deemed study-drug related. CONCLUSION: Porfimer appears to display a safe and tolerable profile when used in patients requiring a second photodynamic therapy within 45 days.